JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B1639 Ridaforolimus (Deforolimus, MK-8669)

Target: mTOR

Summary: MTOR inhibitor

≥49.5 mg/mL
B2180 AS-252424

Target: Akt|PI3K

Summary: PI3Kγ inhibitor,novel and potent

insoluble in EtOH; insoluble in H2O; ≥30.5 mg/mL
B1641 WAY-600

Target: mTOR

Summary: MTOR inhibitor

≥12.38 mg/mL
A8169 Everolimus (RAD001)
8 Citation

Target: mTOR

Summary: MTOR inhibitor

≥47.91 mg/mL
B4492 HS-173

Target: PI3K

Summary: novel PI3K inhibitor

≥21.1 mg/mL
B3672 Indirubin

Target: Cyclin-Dependent Kinases|GSK-3

Summary: cyclin-dependent kinases and GSK-3β inhibitor

insoluble in H2O; insoluble in H2O; insoluble in EtOH; ≥13.1 mg/mL
A8309 Perifosine
1 Citation

Target: Akt

Summary: Akt inhibitor
A8315 NU7441 (KU-57788)
4 Citation

Target: PI3K|DNA-PK

Summary: DNA-PK inhibitor

insoluble in EtOH; insoluble in H2O; ≥4.13 mg/mL
A8346 BYL-719
1 Citation

Target: PI3K

Summary: Selective PI3Kα inhibitor

≥22.07 mg/mL
A8488 NVP-BGT226

Target: PI3K|mTOR

Summary: PI3K/mTOR inhibitor,selective and novel

insoluble in EtOH; insoluble in H2O; ≥16.28 mg/mL